In an Era of ctDNA, Is Metabolomics the New Kid on the Block?

Brian A. Van Tine; Costas A. Lyssiotis

doi:10.1158/1078-0432.CCR-21-4180

In an Era of ctDNA, Is Metabolomics the New Kid on the Block?

Brian A. Van Tine, Costas A. Lyssiotis

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Mass action drives the serum homeostasis of metabolites. Recent developments in biofluid metabolomics suggest the potential to harness these changes using small volumes of blood to diagnose, monitor, and risk stratify patients with cancer. This current study may represent a complementary technology to circulating tumor DNA detection.

Original language	English
Pages (from-to)	1477-1478
Number of pages	2
Journal	Clinical Cancer Research
Volume	28
Issue number	8
DOIs	https://doi.org/10.1158/1078-0432.CCR-21-4180
State	Published - Apr 15 2022

Access to Document

10.1158/1078-0432.CCR-21-4180

Cite this

@article{d98e01028e04432fbd32b00a90ead4b1,

title = "In an Era of ctDNA, Is Metabolomics the New Kid on the Block?",

abstract = "Mass action drives the serum homeostasis of metabolites. Recent developments in biofluid metabolomics suggest the potential to harness these changes using small volumes of blood to diagnose, monitor, and risk stratify patients with cancer. This current study may represent a complementary technology to circulating tumor DNA detection.",

author = "{Van Tine}, {Brian A.} and Lyssiotis, {Costas A.}",

note = "Funding Information: B.A. Van Tine reports grants from Pfizer, Merck, and Tracon Pharm; grants, nonfinancial support, and other support from GlaxoSmithKline; and personal fees from Epizyme, ADRx, Ayala Pharmaceuticals, Cytokinetics, Bayer, Targeted Oncology, Adaptimmune Limited, Bionest Partners (Healthcare/Education), Intelli-sphere LLC, Polaris, Deciphera Pharmaceuticals, Novartis, Lilly, Apexigen, and Daiichi Sankyo outside the submitted work; in addition, B.A. Van Tine has a patent for Accuronix Therapeutics issued. C.A. Lyssiotis reports personal fees from Astellas Pharmaceuticals, Odyssey Therapeutics, and T-knife Therapeutics outside the submitted work; in addition, C.A. Lyssiotis has a patent for targeting the GOT1-pathway as a therapeutic approach, US Patent No: 2015126580-A1; US Patent No: 20190136238; International Patent No: WO2013177426-A2 issued. Publisher Copyright: {\textcopyright} 2022 American Association for Cancer Research.",

year = "2022",

month = apr,

day = "15",

doi = "10.1158/1078-0432.CCR-21-4180",

language = "English",

volume = "28",

pages = "1477--1478",

journal = "Clinical Cancer Research",